IL123721A - History of imidazole with affinities for alpha 2 receptors, methods for their preparation and pharmaceutical preparations containing them - Google Patents

History of imidazole with affinities for alpha 2 receptors, methods for their preparation and pharmaceutical preparations containing them

Info

Publication number
IL123721A
IL123721A IL12372196A IL12372196A IL123721A IL 123721 A IL123721 A IL 123721A IL 12372196 A IL12372196 A IL 12372196A IL 12372196 A IL12372196 A IL 12372196A IL 123721 A IL123721 A IL 123721A
Authority
IL
Israel
Prior art keywords
hydrogen
alkyl
derivative
hydroxy
derivative according
Prior art date
Application number
IL12372196A
Other languages
English (en)
Hebrew (he)
Other versions
IL123721A0 (en
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of IL123721A0 publication Critical patent/IL123721A0/xx
Publication of IL123721A publication Critical patent/IL123721A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
IL12372196A 1995-10-03 1996-10-02 History of imidazole with affinities for alpha 2 receptors, methods for their preparation and pharmaceutical preparations containing them IL123721A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9520150.5A GB9520150D0 (en) 1995-10-03 1995-10-03 New imidazole derivatives
PCT/FI1996/000518 WO1997012874A1 (en) 1995-10-03 1996-10-02 Imidazole derivatives having affinity for alpha2 receptors activity

Publications (2)

Publication Number Publication Date
IL123721A0 IL123721A0 (en) 1998-10-30
IL123721A true IL123721A (en) 2004-07-25

Family

ID=10781676

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12372196A IL123721A (en) 1995-10-03 1996-10-02 History of imidazole with affinities for alpha 2 receptors, methods for their preparation and pharmaceutical preparations containing them

Country Status (29)

Country Link
US (2) US6313311B1 (lt)
EP (1) EP0888309B1 (lt)
JP (1) JP4129891B2 (lt)
KR (1) KR19990064013A (lt)
CN (1) CN1068592C (lt)
AT (1) ATE234819T1 (lt)
AU (1) AU708002B2 (lt)
BG (1) BG63916B1 (lt)
CA (1) CA2231535C (lt)
CZ (1) CZ291576B6 (lt)
DE (1) DE69626862T2 (lt)
DK (1) DK0888309T3 (lt)
EE (1) EE04436B1 (lt)
ES (1) ES2195013T3 (lt)
GB (1) GB9520150D0 (lt)
HU (1) HU224197B1 (lt)
IL (1) IL123721A (lt)
LT (1) LT4460B (lt)
LV (1) LV12108B (lt)
NO (1) NO311024B1 (lt)
NZ (1) NZ319169A (lt)
PL (1) PL189110B1 (lt)
PT (1) PT888309E (lt)
RO (1) RO120409B1 (lt)
RU (1) RU2188194C2 (lt)
SI (1) SI9620111B (lt)
SK (1) SK283542B6 (lt)
UA (1) UA49847C2 (lt)
WO (1) WO1997012874A1 (lt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA981080B (en) * 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
AU2002254265B2 (en) * 1997-12-04 2008-05-15 Allergan, Inc. Imidiazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
CN1284066A (zh) * 1997-12-04 2001-02-14 阿勒根销售公司 对α2B或2B/2C肾上腺素能受体具有激动剂样活性的取代咪唑衍生物
DE69923698T2 (de) * 1998-09-28 2006-01-12 Orion Corp. Verwendung von 3-(1h-imidazol-4-ylmethyl)-indan-5-ol zur herstellung eines medikamentes zur intraspinalen, intrathekalen und epiduralen anwendung
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
EP1196168A2 (en) * 1999-06-25 2002-04-17 Orion Corporation Method of admistering an imidazole derivative to obtain analgesia
RU2259827C2 (ru) 1999-10-29 2005-09-10 Орион Корпорейшн Лечение или предупреждение гипотензии и шока
US6388090B2 (en) 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
ES2247107T3 (es) * 2000-05-08 2006-03-01 Orion Corporation Nuevos indanilimidazoles policiclicos con actividad adrenergica.
TW200930291A (en) * 2002-04-29 2009-07-16 Bayer Cropscience Ag Pesticidal heterocycles
FR2839719B1 (fr) * 2002-05-16 2004-08-06 Pf Medicament Nouveaux composes imidazoliques, leur procede de preparation et leur utilisation a titre de medicaments
FI20022159A0 (fi) * 2002-12-05 2002-12-05 Orion Corp Uusia farmaseuttisia yhdisteitä
FI116292B (fi) * 2003-01-08 2005-10-31 Juvantia Pharma Ltd Oy Menetelmä substituoitujen imidatsolijohdannaisten valmistamiseksi ja menetelmässä käytettäviä välituotteita
DE102004035322A1 (de) * 2004-07-21 2006-02-16 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
AU2006283104A1 (en) 2005-08-25 2007-03-01 Pharmacopeia, Inc. Imidazole derivatives as functionally selective alpha2C adrenoreceptor agonists
EP1934203B1 (en) 2005-08-25 2010-08-18 Schering Corporation 3,4-dihydro-2H-benzo[1,4]oxazine and 3,4-dihydro-2H-benzo[1,4]thiazine COMPOUNDS AS ALPHA2C ADRENORECEPTOR AGONISTS
JP2009524618A (ja) * 2006-01-27 2009-07-02 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ障害の処置における２−イミダゾールの使用
CA2666762C (en) 2006-10-19 2014-12-30 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
CA2668454A1 (en) 2006-11-02 2008-05-08 F. Hoffmann-La Roche Ag Substituted 2-imidazoles
KR101134226B1 (ko) * 2006-11-16 2012-04-10 에프. 호프만-라 로슈 아게 치환된 4-이미다졸
JP2010513238A (ja) 2006-12-13 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー 微量アミン関連受容体（ｔａａｒ）に対するリガンドとしての新規２−イミダゾール
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
EP2114906B1 (en) 2007-02-02 2014-08-06 F. Hoffmann-La Roche AG 2-aminooxazolines as taar1 ligands for cns disorders
CA2678072A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
WO2008100456A2 (en) 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
CA2678069A1 (en) 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
ES2525229T3 (es) 2007-02-15 2014-12-19 F. Hoffmann-La Roche Ag 2-aminooxazolinas como ligandos de TAAR1
EP2173720A2 (en) 2007-07-02 2010-04-14 F. Hoffmann-Roche AG 2-imidazolines having a good affinity to the trace amine associated receptors (taars)
EP2173719A1 (en) 2007-07-03 2010-04-14 F. Hoffmann-Roche AG 4-imidazolines and their use as antidepressants
CA2694362A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
JP5341084B2 (ja) 2007-08-03 2013-11-13 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
WO2009105504A2 (en) 2008-02-21 2009-08-27 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
EP2356106A1 (en) 2008-10-07 2011-08-17 Schering Corporation Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
JP6172938B2 (ja) 2009-05-15 2017-08-02 レクロ・ファーマ，インコーポレーテッド デクスメデトミジンの舌下組成物およびその使用方法
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8673950B2 (en) 2010-11-02 2014-03-18 Hoffmann-Laroche Inc. Dihydrooxazol-2-amine derivatives
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) * 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
PE20142314A1 (es) 2011-12-11 2015-01-23 Recro Pharma Inc Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
BR112014015832A8 (pt) 2012-01-12 2017-07-04 Hoffmann La Roche derivados heterocíclicos como receptores associados com aminas vistigiais (taars)
SG11201501958QA (en) 2012-09-14 2015-04-29 Hoffmann La Roche Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease
CN104603129A (zh) * 2012-09-17 2015-05-06 霍夫曼-拉罗奇有限公司 三唑甲酰胺衍生物
WO2015165085A1 (en) 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
CN106470994B (zh) 2014-08-27 2019-09-24 豪夫迈·罗氏有限公司 用于治疗cns疾病的取代的吡嗪并[2,1-a]异喹啉衍生物
EP3186224B1 (en) 2014-08-27 2021-04-21 F. Hoffmann-La Roche AG Substituted azetidine derivatives as taar ligands
KR102537050B1 (ko) 2016-03-17 2023-05-26 에프. 호프만-라 로슈 아게 Taar의 작용제로서 활성을 갖는 5-에틸-4-메틸-피라졸-3-카복스아미드 유도체
CN116496261B (zh) * 2023-03-09 2025-06-27 中国人民解放军军事科学院军事医学研究院 4-(1h)-咪唑类衍生物及其医药用途
CN118684628B (zh) * 2024-05-20 2025-06-17 中国人民解放军军事科学院军事医学研究院 取代二氢茚基咪唑类化合物及其制备方法和用途
CN119424420B (zh) * 2024-11-15 2025-11-21 中国人民解放军军事科学院军事医学研究院 取代二氢茚基咪唑类化合物的抗肿瘤用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636002A (en) * 1969-12-15 1972-01-18 Janssen Pharmaceutica Nv 1-(2-halobenzyloxy-1-indanyl)-imidazoles
ES8503669A1 (es) * 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
US4634705A (en) * 1984-06-06 1987-01-06 Abbott Laboratories Adrenergic amidines
US4659730A (en) * 1984-06-18 1987-04-21 Eli Lilly And Company Aromatase inhibiting imidazole derivatives
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
FI81092C (fi) * 1986-05-15 1990-09-10 Farmos Oy Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat.
US4878940A (en) * 1987-04-02 1989-11-07 Janssen Pharmaceutica N.V. Herbicidal 1,5-substituted 1H-imidazoles
IL91542A0 (en) * 1988-10-06 1990-04-29 Erba Carlo Spa N-imidazolyl-and n-imidazolyl-methyl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them
GB2225782A (en) * 1988-12-09 1990-06-13 Farmos Group Limited Imidazole derivatives useful for treatment of diabetes
GB9127050D0 (en) * 1991-12-20 1992-02-19 Orion Yhtymae Oy Substituted imidazole derivatives and their preparation and use
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives

Also Published As

Publication number Publication date
DE69626862T2 (de) 2003-12-24
HUP9802927A3 (en) 2003-02-28
SK283542B6 (sk) 2003-09-11
SI9620111B (en) 2001-12-31
JP4129891B2 (ja) 2008-08-06
PL328167A1 (en) 1999-01-18
EP0888309B1 (en) 2003-03-19
EP0888309A1 (en) 1999-01-07
ES2195013T3 (es) 2003-12-01
ATE234819T1 (de) 2003-04-15
US6479530B2 (en) 2002-11-12
CZ101898A3 (cs) 1998-09-16
UA49847C2 (uk) 2002-10-15
WO1997012874A1 (en) 1997-04-10
RU2188194C2 (ru) 2002-08-27
NO981496L (no) 1998-04-02
US20020007074A1 (en) 2002-01-17
JP2000507914A (ja) 2000-06-27
HK1014951A1 (en) 1999-10-08
IL123721A0 (en) 1998-10-30
CZ291576B6 (cs) 2003-04-16
CN1198741A (zh) 1998-11-11
DK0888309T3 (da) 2003-04-22
EE9800101A (et) 1998-10-15
LV12108A (lv) 1998-08-20
PL189110B1 (pl) 2005-06-30
DE69626862D1 (de) 2003-04-24
LT4460B (lt) 1999-02-25
CN1068592C (zh) 2001-07-18
SI9620111A (sl) 1998-10-31
BG63916B1 (bg) 2003-06-30
HUP9802927A2 (hu) 1999-10-28
PT888309E (pt) 2003-07-31
GB9520150D0 (en) 1995-12-06
SK43998A3 (en) 1998-10-07
NZ319169A (en) 1999-07-29
EE04436B1 (et) 2005-02-15
AU708002B2 (en) 1999-07-29
RO120409B1 (ro) 2006-01-30
NO981496D0 (no) 1998-04-02
US6313311B1 (en) 2001-11-06
LT98057A (lt) 1998-09-25
KR19990064013A (ko) 1999-07-26
HU224197B1 (hu) 2005-06-28
AU7132796A (en) 1997-04-28
NO311024B1 (no) 2001-10-01
BG102324A (en) 1999-01-29
CA2231535A1 (en) 1997-04-10
LV12108B (en) 1998-10-20
CA2231535C (en) 2005-09-20

Similar Documents

Publication Publication Date Title
EP0888309B1 (en) Imidazole derivatives having affinity for alpha2 receptors activity
US6972299B2 (en) Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
FI91857B (fi) Menetelmä terapeuttisesti aktiivisten alfa-heterosykleillä substituoitujen tolunitriilien valmistamiseksi
JP2009524616A (ja) Ｃｎｓ疾患のための４−イミダゾール誘導体の使用
CA2190865A1 (fr) Derives d'imidazole (ant)agonistes du recepteur h3 de l'histamine
FI83310C (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 4,5-substituerade 2-/3-/4-(halogenfenyl)-1- piperazinyl/propyl/-2,4-dihydro-3h-1,2,4-triazol-3-onderivat.
FI81092B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat.
MXPA02006872A (es) Nuevos derivados de imidazol.
HK1014951B (en) Imidazole derivatives having affinity for alpha2 receptors activity
JPH08509502A (ja) イミダゾールリポキシゲナーゼ阻害剤

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired